Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evotec SE - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EVO
Nasdaq
2834
www.evotec.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evotec SE
Evotec shares rise after second IND acceptance with Bristol Myers
- Nov 19th, 2026 2:10 am
Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance
- Nov 19th, 2026 12:06 am
Here's Why Evotec (EVO) Looks Ripe for Bottom Fishing
- Nov 18th, 2026 6:55 am
Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing
- Nov 16th, 2026 8:45 am
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
- Nov 15th, 2026 11:57 pm
Evotec SE (EVOTF) (Q3 2026) Earnings Call Highlights: Near-Breakeven EBITDA, Horizon Savings ...
- Nov 5th, 2026 6:16 pm
Evotec SE (EVO) Q3 2026 Earnings Call Transcript
- Nov 5th, 2026 2:14 pm
What Evotec (EVO) Said on Its Q3 Earnings Call
- Nov 5th, 2026 1:14 pm
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
- Nov 5th, 2026 12:18 am
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
- Oct 29th, 2026 1:00 am
Did Evotec’s 60% Drop Catch You Out? What Investors Missed
- Oct 25th, 2026 10:06 am
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
- Oct 15th, 2026 12:04 am
Evotec shares jump after preliminary 9-month revenue, EBITDA top estimates
- Oct 14th, 2026 1:47 am
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
- Sep 29th, 2026 3:27 am
Evotec Announces Chief Scientific Officer Transition
- Sep 29th, 2026 12:04 am
APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
- Sep 28th, 2026 10:00 pm
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
- Sep 24th, 2026 2:02 am
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share
- Sep 23rd, 2026 2:10 am
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market
- Sep 23rd, 2026 2:08 am
Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030
- Sep 22nd, 2026 2:32 am
Scroll